Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial studying the administration of NanoDoce as a direct injection to the
bladder wall immediately after tumor resection and as an intravesical instillation. All
participants will receive NanoDoce, and will be evaluated for safety and tolerability, as
well as the potential effects of NanoDoce on urothelial carcinoma.